Emerging Diagnostic Technologies for Use in Psychiatric Indications
Decision Resources
May 29, 2008 38 Pages - SKU: DECR1799173
|
|
The diagnosis of psychiatric diseases is an inexact science and a slow process for physicians. No laboratory
tests are available to determine the exact disease-or treatment. New diagnostic technologies could offer
earlier, more specific diagnosis of a psychiatric disease and even direct potential drug therapy. In this report,
we discuss the treatment challenges that confront physicians and patients and review current and emerging
diagnostic tests that are expected to change the way in which psychiatric diseases are diagnosed. This report
also features three Expert Commentaries, two offering input from the diagnostic technology industry, and
one highlighting Decision Resources' primary research with physicians who discuss their views of biomarkerbased
diagnostic tests for psychiatry.
Get the Answers You Need to Shape Your Strategy
- The diagnosis of mental illness is far from an exact science, with no laboratory tests to confirm a disorder or
offer treatment strategies. What technologies are emerging that will expedite diagnosis and treatment of
psychiatric disorders? How will these technologies affect R&D within the pharmaceutical industry?
- EEG, molecular, genetic, and imaging diagnostics are all poised for use in the field of psychiatry.
How will the technologies that exist to aid diagnosis expand into the field of mental health?
What companies already have clinical trials under way and what diagnostic tools are they
using? How will these studies target patient response to some of today's most popular
psychiatric drugs? What challenges do manufacturers face when developing these diagnostics?
- Expert Commentaries: two company executives and one market analyst discuss the impact of
novel diagnostics in the psychiatric arena. What are thought leaders saying about the potential
for biomarkers in mental health diagnosis and treatment? How will a new EEG tool help
psychiatrists target drug therapy in their patients? How can gene-expression profiles lead to
differential diagnoses or offer insight into disease-specific subtyping?
Scope
- Difficulties diagnosing mental illness : addressing similar symptomatology; multiple mental
illnesses in one patient; challenges in determining optimal treatment; current medical practice for
psychiatric indications.
- Current and emerging diagnostic technologies for psychiatric indications: EEG (Aspect
Medical Systems, CNS Response, Memory Pharmaceuticals/Roche); molecular diagnostics (Clinical
Data, CombiMatrix, Curidium Medica, Roche/Affymetrix, Vanda Pharmaceuticals); diagnostic
imaging (Alseres).
- Psychiatric disorders: attention-deficit/hyperactivity disorder; autism spectrum disorder; bipolar
disorder; major depression; schizophrenia; psychotic disorders.
- Business considerations: review of partnerships and licensing activities; benefits of drug/
theranostic codevelopment; challenges and opportunities.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- The Importance of Diagnostic Technologies for Psychiatric Indications
- Value of Biomarker-Based Diagnostics for Psychiatric Diseases
- Difficulties in Diagnosing Psychiatric Illness
- Presentation of Prodromal Symptoms Can Be Slow and Variable
- Several Disorders May Have Similar Symptomatology
- Patients with Multiple Mental Illnesses May be Difficult to Diagnose
- Some Mental Illnesses May Be Broad Categories of Diseases
- Challenges in Determining Optimal Treatment
- Current Medical Practice for Psychiatric Indications
- Current and Emerging Diagnostic Technologies for Psychiatric Indications
- Electroencephalography
- Aspect Medical Systems
- CNS Response
- Memory Pharmaceuticals/Roche and Envivo Pharmaceuticals
- Molecular Diagnostics
- Clinical Data
- CombiMatrix
- Curidium Medica
- Roche/Affymetrix
- Vanda Pharmaceuticals
- Diagnostic Imaging
- Outlook
- Appendix A. Thought Leaders Consulted for This Report
- Appendix B. Bibliography
- Expert Commentaries
- What Do Thought Leaders Say About the Potential Use of Biomarkers in Psychiatric Diagnosis and Treatment?
- Carlos Dedesma, Analyst, Decision Resources, Inc.
- The Potential for rEEG to Create Win-Win Situations for Stakeholders
- Leonard Brandt, CEO, CNS Response
- Disentangling Patient Populations to Develop More-Effective Drug Therapies
- Anne T. Bruinvels, Ph.D., Founder and CSO, Curidium Medica
- Sidebar
- 510(k) vs. PMA
- Tables
- 1. Diagnostic Collaborations in Psychiatric Indications, 2004-March 2008
- 2. Roche’s AmpliChip CYP450 Test: Summary of Attributes
- 3. Major Opportunities and Challenges for Psychiatric Diagnostics
- A. Drug Development Benefits by Development Phase
- Figures
- 1. How Diagnostic Technologies Can Increase Treatment Effi cacy
- 2. Referenced-EEG Sample Report to Physicians from CNS Response
- A. Medications Predicted by rEEG
- B. Schematic Overview of the Studies Undertaken by Curidium to Identify a Blood Diagnostic Tool to Select Schizophrenia and Bipolar Disorder Patient Subgroups in the Clinic
Share this report
Other tasks Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
